On September 10, 2026, Yarrow Bioscience, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC to issue and sell 5,769,231 shares of its common stock at a public offering price of $26.00 per share.
The company also granted the underwriters an option to purchase up to an additional 865,384 shares at the same price. This option was fully exercised on September 11, 2026.
According to the filing, the net proceeds from the offering, including the exercised option, are expected to be approximately $161.8 million. This amount reflects the deduction of underwriting discounts and commissions and estimated offering expenses.
The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-277609), which was declared effective by the SEC on August 19, 2026. A final prospectus supplement dated September 10, 2026, was filed with the SEC on September 11, 2026.
The offering is scheduled to close on September 14, 2026. Additionally, the company’s directors and executive officers have entered into lock-up agreements, agreeing not to sell or dispose of shares of common stock for a period of 60 days after the date of the final prospectus supplement.
